Philip Black

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1

Azithromycin for Early <i>Pseudomonas</i> Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial

Nicole Mayer-Hamblett, George Retsch‐Bogart, Margaret Kloster et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 96 citations · Full text

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function

Wayne J. Morgan, Donald R. VanDevanter, David J. Pasta et al. · The Journal of Pediatrics · 2015 · 59 citations

Advanced Lung Disease, Forced Expiratory Volume, Pulmonary Physiology +6

Increased Fat Absorption From Enteral Formula Through an In‐line Digestive Cartridge in Patients With Cystic Fibrosis

Steven D. Freedman, David M. Orenstein, Philip Black et al. · Journal of Pediatric Gastroenterology and Nutrition · 2017 · 55 citations · Full text